This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Ardent Health Partners, Inc. (ARDT) and Amphastar Pharmaceuticals (AMPH)

Tipranks - Tipranks - Thu Jun 4, 3:24AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CVRx (CVRX), Ardent Health Partners, Inc. (ARDT) and Amphastar Pharmaceuticals (AMPH).

Claim 55% Off TipRanks

CVRx (CVRX)

In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on CVRx. The company’s shares closed last Tuesday at $5.43.

According to TipRanks.com, Vazquez has 0 stars on 0-5 stars ranking scale with an average return of -9.4% and a 34.0% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Edwards Lifesciences, and Irhythm Technologies. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVRx with a $10.50 average price target.

See today’s best-performing stocks on TipRanks >>

Ardent Health Partners, Inc. (ARDT)

KeyBanc analyst Matthew Gillmor CFA maintained a Hold rating on Ardent Health Partners, Inc. today. The company’s shares closed last Tuesday at $9.27.

According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 38.8% success rate. CFA covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Alignment Healthcare, and InnovAge Holding. ;'>

Ardent Health Partners, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $12.59, which is a 37.4% upside from current levels. In a report issued on May 27, TipRanks – DeepSeek also downgraded the stock to Hold with a $10.00 price target.

Amphastar Pharmaceuticals (AMPH)

Barclays analyst Glen Santangelo assigned a Hold rating to Amphastar Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Tuesday at $18.45.

According to TipRanks.com, Santangelo is a 3-star analyst with an average return of 2.9% and a 50.0% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Bausch Health Companies, and Amneal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Amphastar Pharmaceuticals with a $22.00 average price target.

Read More on CVRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).